Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Cvetinovic, Natasa (55340266600)"

Filter results by typing the first few letters
Now showing 1 - 10 of 10
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Androgen status in non-diabetic elderly men with heart failure
    (2017)
    Loncar, Goran (55427750700)
    ;
    Bozic, Biljana (57203497573)
    ;
    Neskovic, Aleksandar N. (35597744900)
    ;
    Cvetinovic, Natasa (55340266600)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Prodanovic, Nenad (24477604800)
    ;
    Dungen, Hans-Dirk (16024171900)
    ;
    von Haehling, Stephan (6602981479)
    ;
    Radojicic, Zoran (6507427734)
    ;
    Trippel, Tobias (16834210300)
    ;
    Putnikovic, Biljana (6602601858)
    ;
    Markovic-Nikolic, Natasa (57211527501)
    ;
    Popovic, Vera (57294508600)
    Purpose: We aimed at evaluating androgen status (serum testosterone [TT] and estimated free testosterone [eFT]) and its determinants in non-diabetic elderly men with heart failure (HF). Additionally, we investigated its associations with body composition and long-term survival. Methods: Seventy three non-diabetic men with HF and 20 healthy men aged over 55years were studied. Echocardiography, 6-min walk test, grip strength, body composition measurement by DEXA method were performed. TT, sex hormone binding globulin, NT-proBNP, and adipokines (adiponectin and leptin) were measured. All-cause mortality was evaluated at six years of follow-up. Results: Androgen status (TT, eFT) was similar in elderly men with HF compared to healthy controls (4.79±1.65 vs. 4.45±1.68ng/ml and 0.409±0.277 vs. 0.350±0.204nmol/l, respectively). In HF patients, TT was positively associated with NT-proBNP (r=0.371, p =0.001) and adiponectin levels (r=0.349, p =0.002), while inverse association was noted with fat mass (r =−0.413, p <0.001). TT and eFT were independently determined by age, total fat mass and adiponectin levels in elderly men with HF (p<0.05 for all). Androgen status was not predictor for all-cause mortality at six years of follow-up. Conclusions: In non-diabetic men with HF, androgen status is not altered and is not predictive of long-term outcome. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Bone in heart failure
    (2020)
    Loncar, Goran (55427750700)
    ;
    Cvetinovic, Natasa (55340266600)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Isaković, Andjelka (54779767000)
    ;
    von Haehling, Stephan (6602981479)
    There is an increasing interest in osteoporosis and reduced bone mineral density affecting not only post-menopausal women but also men, particularly with coexisting chronic diseases. Bone status in patients with stable chronic heart failure (HF) has been rarely studied so far. HF and osteoporosis are highly prevalent aging-related syndromes that exact a huge impact on society. Both disorders are common causes of loss of function and independence, and of prolonged hospitalizations, presenting a heavy burden on the health care system. The most devastating complication of osteoporosis is hip fracture, which is associated with high mortality risk and among those who survive, leads to a loss of function and independence often necessitating admission to long-term care. Current HF guidelines do not suggest screening methods or patient education in terms of osteoporosis or osteoporotic fracture. This review may serve as a solid base to discuss the need for bone health evaluation in HF patients. © 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Heart failure management in the elderly – a public health challenge
    (2016)
    Cvetinovic, Natasa (55340266600)
    ;
    Loncar, Goran (55427750700)
    ;
    Farkas, Jerneja (25225081600)
    Heart failure (HF) is a rapidly growing public health problem and the leading cause of morbidity, mortality, and hospitalization in populations > 65 years. The elderly HF patients have an increased prevalence of HF with preserved ejection fraction and comorbidities, may present with atypical symptoms and signs, have a higher risk for adverse drug reactions, and worse prognosis as compared with younger patients. Moreover, there is a lack of evidence-based therapies for this population because they are underrepresented in the clinical trials. The elderly are less likely to be evaluated by a cardiologist and to be treated in accordance with recommendations of the current HF guidelines. Although the treatment is improving, it is still suboptimal; therefore, HF in elderly patients requires mobilization of public health services and improvement of treatment strategies. © 2016, Springer-Verlag Wien.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Procalcitonin in heart failure: Hic et nunc
    (2017)
    Cvetinovic, Natasa (55340266600)
    ;
    Isakovic, Andjelka M (54779767000)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Dungen, Hans-Durk (16024171900)
    ;
    Nikolic, Natasa Markovic (58288723700)
    ;
    Loncar, Goran (55427750700)
    Although procalcitonin (PCT) was evaluated for the first time in the setting of heart failure (HF) in 1999, its utility in HF patients is still under examination. Patients with HF have significantly higher plasma PCT concentrations than healthy subjects and PCT levels are associated with severity of HF. It has been confirmed that higher levels of PCT are associated with worse outcomes, such as increased mortality and higher rate of rehospitalization, in HF patients with no evidence of infection. Furthermore, it has been approved that PCT-guided antibiotic treatment in HF patients reduces duration of antibiotic therapy and improves outcomes. This review summarizes current evidence from the published literature of the usefulness and limitations of PCT as a biomarker in HF. © 2017 Future Medicine Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Procalcitonin in heart failure: Hic et nunc
    (2017)
    Cvetinovic, Natasa (55340266600)
    ;
    Isakovic, Andjelka M (54779767000)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Dungen, Hans-Durk (16024171900)
    ;
    Nikolic, Natasa Markovic (58288723700)
    ;
    Loncar, Goran (55427750700)
    Although procalcitonin (PCT) was evaluated for the first time in the setting of heart failure (HF) in 1999, its utility in HF patients is still under examination. Patients with HF have significantly higher plasma PCT concentrations than healthy subjects and PCT levels are associated with severity of HF. It has been confirmed that higher levels of PCT are associated with worse outcomes, such as increased mortality and higher rate of rehospitalization, in HF patients with no evidence of infection. Furthermore, it has been approved that PCT-guided antibiotic treatment in HF patients reduces duration of antibiotic therapy and improves outcomes. This review summarizes current evidence from the published literature of the usefulness and limitations of PCT as a biomarker in HF. © 2017 Future Medicine Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study
    (2018)
    Düngen, Hans-Dirk (16024171900)
    ;
    Tscholl, Verena (54982696400)
    ;
    Obradovic, Danilo (35731962400)
    ;
    Radenovic, Sara (57000170900)
    ;
    Matic, Dragan (25959220100)
    ;
    Musial Bright, Lindy (25642935600)
    ;
    Tahirovic, Elvis (24339336300)
    ;
    Marx, Almuth (57034878400)
    ;
    Inkrot, Simone (35784615000)
    ;
    Hashemi, Djawid (57195309402)
    ;
    Veskovic, Jovan (56951285600)
    ;
    Apostolovic, Svetlana (13610076800)
    ;
    von Haehling, Stephan (6602981479)
    ;
    Doehner, Wolfram (6701581524)
    ;
    Cvetinovic, Natasa (55340266600)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Pieske, Burkert (35499467500)
    ;
    Edelmann, Frank (35366308700)
    ;
    Trippel, Tobias (16834210300)
    ;
    Loncar, Goran (55427750700)
    Aims: In heart failure, various biomarkers are established for diagnosis and risk stratification; however, little is known about the relevance of serial measurements during an episode worsening heart failure (WHF). This study sought to investigate the trajectory of natriuretic peptides and multiple novel biomarkers during hospitalization for WHF and to determine the best time point to predict outcome. Methods and results: MOLITOR (Impact of Therapy Optimisation on the Level of Biomarkers in Patients with Acute and Decompensated Chronic Heart Failure) was an eight-centre prospective study of 164 patients hospitalized with a primary diagnosis of WHF. C-terminal fragment of pre-pro-vasopressin (copeptin), N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), and C-terminal pro-endothelin-1 (CT-proET1) were measured on admission, after 24, 48, and 72 h, and every 72 h thereafter, at discharge and follow-up visits. Their performance to predict all-cause mortality and rehospitalization at 90 days was compared. All biomarkers decreased during recompensation (P < 0.05) except MR-proADM. Copeptin at admission was the best predictor of 90 day mortality or rehospitalization (χ2 = 16.63, C-index = 0.724, P < 0.001), followed by NT-proBNP (χ2 = 10.53, C-index = 0.646, P = 0.001), MR-proADM (χ2 = 9.29, C-index = 0.686, P = 0.002), MR-proANP (χ2 = 8.75, C-index = 0.631, P = 0.003), and CT-proET1 (χ2 = 6.60, C-index = 0.64, P = 0.010). Re-measurement of copeptin at 72 h and of NT-proBNP at 48 h increased prognostic value (χ2 = 23.48, C-index = 0.718, P = 0.00001; χ2 = 14.23, C-index = 0.650, P = 0.00081, respectively). Conclusions: This largest sample of serial measurements of multiple biomarkers in WHF found copeptin at admission with re-measurement at 72 h to be the best predictor of 90 day mortality and rehospitalization. © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Sex-related analysis of short- and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: An evaluation of the RISK-PCI data
    (2013)
    Mrdovic, Igor (10140828000)
    ;
    Savic, Lidija (16507811000)
    ;
    Asanin, Milika (8603366900)
    ;
    Cvetinovic, Natasa (55340266600)
    ;
    Brdar, Natasa (55354494600)
    ;
    Djuricic, Nemanja (55354928200)
    ;
    Stepkovic, Milena (55599820000)
    ;
    Marinkovic, Jelena (7004611210)
    ;
    Perunicic, Jovan (9738988200)
    Background: Unfavourable effect of female sex on short- and long-term clinical outcomes has been demonstrated in unselected ST-elevation acute myocardial infarction (STEMI) patients; the results are conflicting in patients who undergo primary percutaneous coronary intervention (PPCI). The objective of this substudy was to determine whether there are sex-related differences in the 30-day and 1-year clinical outcomes and bleeding after PPCI for STEMI. Methods: We analyzed 2096 STEMI patients enrolled in the Risk Scoring Model to Predict Net Adverse Cardiovascular Outcomes After Primary Percutaneous Coronary Intervention (RISK-PCI) trial from February 2006 to December 2009. Composite efficacy end point comprised all-cause mortality, nonfatal infarction, and stroke. Safety end point was bleeding classified according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. Net adverse cardiovascular events included composite efficacy end point and total bleeding. Results: Women in our study were older and presented later than men. After adjustment for potential confounders, there was no difference between sexes with respect to the composite efficacy end point. A higher rate of total bleeding was observed in women (adjusted odds ratio [OR], 1.67; 95% confidence interval [CI], 1.07-2.61 at 30 days, adjusted OR, 1.63; 95% CI, 1.08-2.47 at 1 year) compared with men. Total bleeding was associated with increased mortality at 30 days (OR, 4.87; 95% CI, 2.79-8.47) and at 1 year (OR, 4.43; 95% CI, 2.79-7.02) after PPCI. Conclusions: We did not find a significant sex-related difference with respect to the composite efficacy end point. Women had a higher rate of total bleeding which was associated with increased short- and long-term mortality. Specific measures aimed at preventing bleeding in women might improve the prognosis of PPCI patients. © 2013 Canadian Cardiovascular Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The β-blocker uptitration in elderly with heart failure regarding biomarker levels: CIBIS-ELD substudy
    (2018)
    Cvetinovic, Natasa (55340266600)
    ;
    Sekularac, Nikola (23981224200)
    ;
    Haehling, Stephan Von (6602981479)
    ;
    Tahirovic, Elvis (24339336300)
    ;
    Inkrot, Simona (35784615000)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Apostolovic, Svetlana (13610076800)
    ;
    Putnikovic, Biljana (6602601858)
    ;
    Waagstein, Finn (56216780700)
    ;
    Gelbrich, Goetz (14119833600)
    ;
    Aleksic, Andja (57206730766)
    ;
    Loncar, Goran (55427750700)
    ;
    Düngen, Hans-Dirk (16024171900)
    Aim: We investigated if the baseline value of mid-regional pro-atrial natriuretic peptide (NP), N-terminal pro-B-type NP and copeptin may be helpful in optimizing β-blocker uptitration in elderly patients with heart failure. Patients & methods: According to the biomarkers’ levels, 457 patients were divided into three subgroups and compared with each other at baseline and 3 months after. Results: All mid-regional pro-atrial NP and N-terminal pro-B-type NP subgroups had significant amelioration of left ventricle ejection fraction and New York Heart Association (NYHA) class after 3 months of β-blocker uptitration (p < 0.001). More prominent improvement of left ventricle ejection fraction and New York Heart Association class was observed in subgroups with lower versus higher NPs levels. Conclusion: NPs levels, unlike copeptin levels, might be useful tool for objective selection of elderly heart failure patients who could have the greatest benefit of forced uptitration. C 2018 Future Medicine Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The β-blocker uptitration in elderly with heart failure regarding biomarker levels: CIBIS-ELD substudy
    (2018)
    Cvetinovic, Natasa (55340266600)
    ;
    Sekularac, Nikola (23981224200)
    ;
    Haehling, Stephan Von (6602981479)
    ;
    Tahirovic, Elvis (24339336300)
    ;
    Inkrot, Simona (35784615000)
    ;
    Lainscak, Mitja (9739432000)
    ;
    Apostolovic, Svetlana (13610076800)
    ;
    Putnikovic, Biljana (6602601858)
    ;
    Waagstein, Finn (56216780700)
    ;
    Gelbrich, Goetz (14119833600)
    ;
    Aleksic, Andja (57206730766)
    ;
    Loncar, Goran (55427750700)
    ;
    Düngen, Hans-Dirk (16024171900)
    Aim: We investigated if the baseline value of mid-regional pro-atrial natriuretic peptide (NP), N-terminal pro-B-type NP and copeptin may be helpful in optimizing β-blocker uptitration in elderly patients with heart failure. Patients & methods: According to the biomarkers’ levels, 457 patients were divided into three subgroups and compared with each other at baseline and 3 months after. Results: All mid-regional pro-atrial NP and N-terminal pro-B-type NP subgroups had significant amelioration of left ventricle ejection fraction and New York Heart Association (NYHA) class after 3 months of β-blocker uptitration (p < 0.001). More prominent improvement of left ventricle ejection fraction and New York Heart Association class was observed in subgroups with lower versus higher NPs levels. Conclusion: NPs levels, unlike copeptin levels, might be useful tool for objective selection of elderly heart failure patients who could have the greatest benefit of forced uptitration. C 2018 Future Medicine Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A substudy of the RISK-PCI trial
    (2013)
    Mrdovic, Igor (10140828000)
    ;
    Savic, Lidija (16507811000)
    ;
    Lasica, Ratko (14631892300)
    ;
    Krljanac, Gordana (8947929900)
    ;
    Asanin, Milika (8603366900)
    ;
    Brdar, Natasa (55354494600)
    ;
    Djuricic, Nemanja (55354928200)
    ;
    Cvetinovic, Natasa (55340266600)
    ;
    Marinkovic, Jelena (7004611210)
    ;
    Perunicic, Jovan (9738988200)
    Stent thrombosis (ST) is an important cause of death after primary percutaneous coronary intervention (pPCI). This substudy aimed at evaluating the usefulness of the RISK-PCI score, originally developed for the prediction of 30-day major adverse cardiovascular events, to predict the occurrence of ST after pPCI. We analyzed 1972 consecutive patients who underwent pPCI with stent implantation between February 2007 and December 2009. Early ST (EST), late ST (LST), and cumulative 1-year ST (CST) were the predefined end points. Definite, probable, and possible ST were included. Models discrimination and calibration to predict ST was tested using receiver-operating characteristics curves and the goodness-of-fit (GoF) test. Sensitivity analyses and 1000-resample bootstrapping were used to evaluate the model's performance. The rates of EST, LST, and CST were 4.6, 1.4, and 6.0 %, respectively. Compared with controls, the cumulative ST group was associated with much higher rates of adverse clinical outcomes at 30-day follow-up (adjusted odds ratio (OR) for death 6.45, adjusted OR for major bleeding 4.41) and at 12-month follow-up (adjusted OR for death 7.35, adjusted OR for major bleeding 4.56). Internal validation confirmed a reasonably good discrimination and calibration of the RISK-PCI score for the prediction of EST (area under the curve (AUC) 0.71, GoF 0.42), LST (AUC 0.69, GoF 0.36), and CST (AUC 0.70, GoF 0.22) after pPCI. ST after pPCI is associated with adverse 30-day and 1-year clinical outcomes. We conclude that the risk of ST could be accurately assessed using the RISK-PCI score, which might help in deciding upon measures aimed at preventing adverse prognosis. © 2012 Springer.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback